IV BUSULFAN-BASED REDUCED INTENSITY REGIMEN (RIC) BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION IS WELL TOLERATE AND EFFECTIVE IN PATIENTS WITH HEMATOLOGICAL DISEASES

被引：0
|
作者：
Castagna, L. [1 ]
Furst, S. [1 ]
El-Cheikh, J. [1 ]
Faucher, C. [1 ]
Vey, N. [1 ]
Bouabdallah, R. [1 ]
Stoppa, A. -M [1 ]
Mohty, M. [2 ]
Chabannon, C. [1 ]
Esterni, B. [1 ]
Blaise, D. [1 ]
机构：
[1] Inst Paoli Calmettes, Marseille, France
[2] CHU Hotel Dieu, Nantes, France
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2010年 / 16卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2009.12.417
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
373
引用
收藏
页码：S295 / S295
页数：1
相关论文
共 50 条
  • [21] Prognostic Impact of Hematopoietic Recovery After Fludarabine, IV Busulfan and Antithymocyte Globulins (FB2 regimen) Reduced-Intensity Conditioning Regimen (RIC) Allogeneic Stem Cell Transplantation (allo-SCT)
    Lebourgeois, Amandine
    Loirat, Marion
    Tessoulin, Benoit
    Lestang, Elsa
    Peteriin, Pierre
    Malard, Florent
    Mohr, Catherine
    Touzeau, Cyrille
    Blin, Nicolas
    Clavert, Aline
    Augeul-Meunier, Karine
    Guillaume, Thierry
    Delaunay, Jacques
    Ayari, Sameh
    Brissot, Eolia
    Dubruille, Viviane
    Mahe, Beatrice
    Roland, Virginie
    Gastinne, Thomas
    Le Gouill, Steven
    Moreau, Philippe
    Mohty, Mohamad
    Planche, Lucie
    Chevallier, Patrice
    BLOOD, 2012, 120 (21)
  • [22] Busulfan-based reduced toxicity conditioning regimen used in hematopoietic stem cell transplantation in HLH patients results in sustained donor chimerism
    Goode, Erin
    Miller, Holly
    Salzberg, Dana
    Campbell, Courtney
    Beebe, Kristen
    Schwalbach, Charlotte
    Adams, Roberta H.
    Ngwube, Alexander
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2021, 38 (04) : 410 - 416
  • [23] A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation
    G S Hobbs
    N Kaur
    P Hilden
    D Ponce
    C Cho
    H R Castro-Malaspina
    S Giralt
    J D Goldberg
    A A Jakubowski
    E B Papadopoulos
    C Sauter
    G Koehne
    J Yahalom
    S Delvin
    J N Barker
    M-A Perales
    Bone Marrow Transplantation, 2016, 51 : 1010 - 1012
  • [24] A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation
    Hobbs, G. S.
    Kaur, N.
    Hilden, P.
    Ponce, D.
    Cho, C.
    Castro-Malaspina, H. R.
    Giralt, S.
    Goldberg, J. D.
    Jakubowski, A. A.
    Papadopoulos, E. B.
    Sauter, C.
    Koehne, G.
    Yahalom, J.
    Delvin, S.
    Barker, J. N.
    Perales, M-A
    BONE MARROW TRANSPLANTATION, 2016, 51 (07) : 1010 - 1012
  • [25] ABSOLUTE LYMPHOCYTE COUNT KINETICS MAY PREDICT THE CLINICAL OUTCOME AFTER RELATED ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH A BUSULFAN-BASED REDUCED-INTENSITY CONDITIONING REGIMEN
    Yakushijin, K.
    Fukuda, T.
    Saito, B.
    Kurosawa, S.
    Asakura, Y.
    Azuma, T.
    Kim, S. -W
    Mori, S. -i
    Tanosaki, R.
    Heike, Y.
    Takaue, Y.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 137 - 138
  • [26] Reduced intensity conditioning (RIC) and allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients.
    Duerst, RE
    Jacobsohn, D
    Kletzel, M
    BLOOD, 2003, 102 (11) : 435B - 435B
  • [27] Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning
    Hamadani, Mehdi
    Craig, Michael
    Phillips, Gary S.
    Abraham, Jame
    Tse, William
    Cumpston, Aaron
    Gibson, Laura
    Remick, Scot C.
    Bunner, Pamela
    Leadmon, Sonia
    Elder, Patrick
    Hofmeister, Craig
    Penza, Sam
    Efebera, Yvonne
    Andritsos, Leslie
    Garzon, Ramiro
    Benson, Don M., Jr.
    Blum, William
    Devine, Steven M.
    HEMATOLOGICAL ONCOLOGY, 2011, 29 (04) : 202 - 210
  • [28] Allogeneic haematopoietic stem cell transplantation after reduced-intensity regimen containing fludarabine, busulfan, and ATG (Fresenius)
    Brychtova, Y
    Doubek, M
    Mayer, J
    Krejci, M
    Koristek, Z
    Buchtova, I
    BONE MARROW TRANSPLANTATION, 2005, 35 : S209 - S209
  • [29] Myeloablative, Intravenous Busulfan-Based Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies is Safe and Effective in Patients Age 60 and Older
    Lee, Catherine J.
    Vinik, Kristen
    Langebrake, Claudia
    Boyer, Michael
    Couriel, Daniel R.
    Kroeger, Nicolaus
    Zander, Axel
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S332 - S333
  • [30] Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience
    Zaidman, Irina
    Rowe, Jacob M.
    Khalil, Abdalla
    Ben-Arush, Myriam
    Elhasid, Ronit
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (06) : 1043 - 1048
12345